Fleischner 2017 vs Lung-RADS for incidental pulmonary nodule management: which do you follow?

48M undergoing CT abdomen for renal colic. Incidentally found to have a 7mm part-solid pulmonary nodule in the right upper lobe. The solid component measures approximately 4mm. No prior CT for comparison. Patient is a non-smoker.

The dilemma: Fleischner 2017 guidelines recommend follow-up CT at 3 to 6 months for part-solid nodules > 6mm. But the patient's referring urologist wants to know "is it cancer?" and is pushing for immediate PET-CT.

Questions:

Do you follow Fleischner 2017 strictly, or do you modify based on clinical judgment?
At what solid component size do you recommend biopsy vs surveillance?
Is PET-CT useful for sub-centimeter part-solid nodules?
How do you communicate incidental findings to non-pulmonary specialists?

This is a common scenario, and the communication aspect is as important as the medical management.

1. Fleischner adherence: I follow Fleischner 2017 as the baseline. For this case (7mm part-solid, solid component 4mm, non-smoker), the recommendation is follow-up CT at 3 to 6 months. If the nodule persists, annual CT for 5 years. This is evidence-based and avoids unnecessary invasive procedures.

2. Solid component threshold: The critical number is the solid component size, not the total nodule size. For part-solid nodules:

Solid component < 6mm: surveillance per Fleischner
Solid component 6 to 8mm: short-interval follow-up (3 months)
Solid component > 8mm: consider PET-CT or biopsy With a 4mm solid component, this patient falls clearly into the surveillance category.

3. PET-CT for sub-centimeter nodules: Not useful. The spatial resolution of PET is approximately 7 to 10mm. A 7mm part-solid nodule with a 4mm solid component will not reliably show FDG uptake even if malignant. The false-negative rate for sub-centimeter nodules on PET exceeds 50%. Doing a PET-CT here would add cost, radiation, and potential false reassurance.

4. Communication: I include structured recommendations in my radiology report using the Lung-RADS or Fleischner framework, with a specific follow-up timeline. I also dictate a brief plain-language summary: "Incidental lung nodule requiring follow-up CT in 3 months. Not suspicious for immediate malignancy. Not an emergency."

From the pulmonology perspective, I agree with Dr. Subramanian's Fleischner-based approach. The one modification I make in practice: I involve the patient in shared decision-making earlier than the guidelines suggest. Some patients have significant anxiety about incidental findings, and offering a 3-month follow-up CT with a clear explanation of the low malignancy risk (< 1% for a 7mm part-solid nodule in a non-smoker younger than 50) is therapeutic in itself.

I also document the solid component size, morphology (smooth vs spiculated margins), and location in my clinic notes, because Fleischner 2017 explicitly states that "additional factors such as morphology and location may warrant more aggressive follow-up." A spiculated margin, even in a sub-centimeter nodule, pushes me toward shorter follow-up intervals.

2 Answers